Sign In
Buy ALKS
$48.07
+2.05 (+4.45%)
At Close: Jun 23, 2026
Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton
03:49pm, Friday, 19'th Jun 2026
Alkermes plc maintains a Buy rating, driven by the accretive Avadel Pharmaceuticals acquisition and strong pipeline progress. Company bolstered its hypersomnolence portfolio with LUMRYZ, which deliver
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
04:15pm, Wednesday, 17'th Jun 2026
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced detailed positive results from the Vibrance-2 phase 2 dose-ranging study evaluating alixorexton in patients with narcolepsy type 2
ALKS' Sleep Disorder Drug Gets Orphan Drug Tags in the U.S. & Europe
11:15am, Tuesday, 16'th Jun 2026
Alkermes wins orphan drug designations in the United States and Europe for alixorexton for treating idiopathic hypersomnia and narcolepsy, respectively.
Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe
07:00am, Monday, 15'th Jun 2026
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced that alixorexton, a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of na
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
07:14am, Thursday, 11'th Jun 2026
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect
Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears
02:09pm, Wednesday, 10'th Jun 2026
Alkermes NASDAQ: ALKS executives said the company is entering a period of heightened execution as it advances its orexin agonist program into late-stage development, integrates Avadel and prepares for
Alkermes plc (ALKS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
12:32pm, Wednesday, 10'th Jun 2026
Alkermes plc (ALKS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Alkermes PLC (ALKS) Shares Surge 4.4% -- What GF Score of 74 Tells Investors
07:57pm, Tuesday, 09'th Jun 2026
On June 09, 2026, Alkermes PLC (ALKS) shares rose 4.4% today, bringing the current price to $44.28. The stock has seen considerable price movement over the past
Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech
08:45am, Friday, 05'th Jun 2026
Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns.
Alkermes (ALKS) Up 21.1% Since Last Earnings Report: Can It Continue?
12:31pm, Thursday, 04'th Jun 2026
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research
07:00am, Thursday, 04'th Jun 2026
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present new data from its industry-leading portfolio of sleep medicine research at SLEEP 2026, the 40th annual meeting of
Alkermes PLC (ALKS) Stock Up 4.8% but GF Value Says Overvalued -- GF Score: 76/100
06:51pm, Thursday, 28'th May 2026
On May 28, 2026, Alkermes PLC (ALKS) shares rose 4.8% to a current price of $39.94. This price is within a 52-week range of $25.17 to $40.79, reflecting a stron
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present clinical and real-world data related to the company's psychiatry and orexin portfolios at the American Society of
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the presentation of accepted research at key scientific conferences this spring related to its psychiatry products—LYBALVI® (ola
Alkermes Gains Momentum After Sleep Disorder Trial Clears Key Hurdles
02:27pm, Tuesday, 12'th May 2026
Alkermes Inc. plc (NASDAQ:ALKS) stock is trading higher on Tuesday following the announcement of positive topline results from the REVITALYZ phase 3 study evaluating LUMRYZ extended-release oral suspe
